News Releases

December 1, 2020
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
CAMBRIDGE, Mass. , Dec. 1, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of an underwritten public offering of 10,256,411 shares of its common stock,
November 30, 2020
Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock
CAMBRIDGE, Mass. , Nov. 30, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $60,000,000 of shares of its common
November 30, 2020
Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer
Highly skilled leader in drug development and manufacturing with nearly 20 years of experience at Array BioPharma as Vice President of Supply Chain and Manufacturing CAMBRIDGE, Mass. , Nov. 30, 2020 /PRNewswire/ --  Cogent Biosciences, Inc.  ("Cogent") (NASDAQ: COGT), a biotechnology company
November 20, 2020
Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference
CAMBRIDGE, Mass. , Nov. 20, 2020 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will participate in a virtual
November 18, 2020
Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020
Majority of patients treated with PLX9486 + sunitinib experienced clinical benefit with a median PFS of 12 months and 20% ORR, including a complete response, in a heavily pre-treated GIST population; 27% of patients remain on therapy out 27-34 months   Combination showed no dose limiting toxicities
November 12, 2020
Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference
CAMBRIDGE, Mass. , Nov. 12, 2020 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present a corporate
November 9, 2020
Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
Andrew Robbins appointed President, CEO and Director   Final results from PLX9486 + sunitinib Phase 1/2 study in GIST patients selected for oral presentation at Connective Tissue Oncology Society (CTOS) 2020 meeting   Ended quarter with $129.4 million in cash, including proceeds from $104.4M Series
November 5, 2020
Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 5, 2020 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will virtually present a
October 26, 2020
Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer
Seasoned executive with deep experience developing precision medicines for genetically defined diseases, most recently as COO of Array Biopharma CAMBRIDGE, Mass. , Oct. 26, 2020 /PRNewswire/ -- Cogent Biosciences , Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing
October 5, 2020
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress
Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients   Company on track to advance CGT9486 into Systemic Mastocytosis patients in 1H21   Abstract selected for oral presentation at CTOS 2020   New data from the Phase 1/2 clinical trial of
Displaying 1 - 10 of 18
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.